Key Highlights

● Preliminary third-quarter 2026 Revenue was about $1.22 million, up 256% from the second quarter.

● The jump reflects the August REZENOPY launch and higher sales of ARBLI.

● A 1-for-25 reverse split on October 5, 2026 resolved the Nasdaq bid-price matter.

● Second-quarter operating expenses of $3.0 million still far exceeded gross profit.

Scienture Holdings, Inc. (NASDAQ:SCNX), a specialty pharmaceutical holding company, reported preliminary third-quarter 2026 revenue of about $1.22 million on October 13, up 256% from $343,639 in the second quarter. The increase reflects the August launch of REZENOPY and higher sales of ARBLI. The base is very small, and the company is still loss-making, so investors may view the trend alongside its financing position, its going-concern commentary and recent Nasdaq compliance events.

Latest Company Context

Scienture operates through its Subsidiary Scienture, LLC and sells ARBLI, a losartan potassium oral suspension, and REZENOPY, a 10 mg naloxone nasal spray. Revenue was $56,325 in the first quarter and $343,639 in the second, with first-half revenue of $399,964. Second-quarter net loss was $2.82 million, a 58% improvement year over year, and cash, equivalents and restricted cash were $11.2 million at June 30. Preliminary third-quarter figures are unaudited.

ARBLI wholesale unit sales rose 74% sequentially, and REZENOPY contributed initial wholesale shipments. The company has also reported Patent grants running to 2041 for both products and group purchasing agreements that it says reach about 60% of the US institutional market. Second-quarter gross Margin was reported near 97.7%, but Gross Profit remains small relative to expenses, with second-quarter operating expenses of $3.0 million and an operating loss of $2.7 million.

Key Business and index Drivers

Management has said it expects revenue to keep rising sequentially as both products scale, and it has targeted profitability in 2027, though that timeline is not assured and has provided no numeric guidance. Drivers may include prescription growth, formulary additions and the sales force that was scheduled to begin operations on June 1. Financing is another factor: the company secured $11.0 million in non-dilutive debt. Its listing position also changed.

After receiving a minimum bid price notice in October 2025 and two 180-day extensions, it effected a 1-for-25 Reverse Stock Split on October 5, 2026, and Nasdaq confirmed on October 19 that the stock had closed at or above $1.00 for ten consecutive trading days, closing the matter. Operating expenses of about $3 million in the second quarter still exceeded gross profit by a wide margin. One third-party summary estimated an annualised revenue run rate near $5 million; that figure is a derived estimate rather than company guidance, and it would remain modest against the current cost base.

What Investors Should Watch

The key upcoming item is the third-quarter Form 10-Q, which may show final revenue, net loss, cash and any commentary on going-concern risk, which has been referenced in coverage of the company. Investors may compare cash against quarterly operating expenses of roughly $3 million to gauge runway, and watch whether revenue continues rising after the REZENOPY launch. Announcements on additional distribution agreements, payer coverage or new product candidates could also matter.

The reverse split increased authorised shares available for future issuance, so any Equity raise could affect dilution. Because Scienture is a micro-cap, trading Liquidity may be thin and price moves can be large. Reverse splits do not alter a company's underlying economics, so investors may focus on cash generation rather than the per-share price. Management's profitability target for 2027 should be viewed as an aspiration, with execution risk around launch pace, reimbursement and competition from other naloxone and generic products.

A Fast Climb From a Small Base

Scienture's revenue trend is rising quickly from a very low base, and the Nasdaq bid-price matter has been closed after the reverse split, removing one near-term listing overhang. Whether growth can approach the cost base remains the central question, with the 10-Q the next verifiable checkpoint, alongside further product-launch updates and any new financing. Investors may also consider how much dilution further Capital raising could involve.